Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.

Autor: Moreno L; Vall d'Hebron University Hospital, Barcelona, Spain., Weston R; University of Birmingham, Birmingham, United Kingdom., Owens C; Children's Hospital Ireland, Dublin, Ireland., Valteau-Couanet D; Institut Gustave Roussy, Paris, France., Gambart M; Hôpital des Enfants, Bordeaux, France., Castel V; Hospital Universitario La Fe, Valencia, Spain., Zwaan CM; Princess Maxima Center, Utrecht, the Netherlands., Nysom K; Rigshospitalet, Copenhagen, Denmark., Gerber N; Universitats-Kinderspital, Zurich, Switzerland., Castellano A; Bambino Gesù Children's Hospital, Rome, Italy., Laureys G; University Hospital Gent, Gent, Belgium., Ladenstein R; St Anna Kinderspital, Vienna, Austria., Rössler J; Inselspital, Universitätsspital Bern, Bern, Switzerland., Makin G; Central Manchester and Manchester Children's University Hospitals NHS Trust, Manchester, United Kingdom., Murphy D; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom., Morland B; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom., Vaidya S; The Royal Marsden NHS Foundation Trust & Institute for Cancer Research, London, United Kingdom., Thebaud E; Hôpital Mère-Enfant, Nantes, France., van Eijkelenburg N; Princess Maxima Center, Utrecht, the Netherlands., Tweddle DA; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom., Barone G; Great Ormond Street Hospital, London, United Kingdom., Tandonnet J; Hôpital des Enfants, Hémato-Oncologie, Bordeaux, France., Corradini N; Centre Léon Bérard, Lyon, France., Chastagner P; Hôpital d'Enfants, Nancy, France., Paillard C; Hôpital de Hautepierre, Strasbourg, France., Bautista FJ; Princess Maxima Center, Utrecht, the Netherlands., Gallego Melcon S; Vall d'Hebron University Hospital, Barcelona, Spain., De Wilde B; University Hospital Gent, Gent, Belgium., Marshall L; The Royal Marsden NHS Foundation Trust & Institute for Cancer Research, London, United Kingdom., Gray J; University Hospital Southampton, Southampton, United Kingdom., Burchill SA; St James University Hospital, Leeds, United Kingdom., Schleiermacher G; Institute Curie, Paris, France., Chesler L; The Royal Marsden NHS Foundation Trust & Institute for Cancer Research, London, United Kingdom., Peet A; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom., Leach MO; The Royal Marsden NHS Foundation Trust & Institute for Cancer Research, London, United Kingdom., McHugh K; Great Ormond Street Hospital, London, United Kingdom., Hayes R; Children's Hospital Ireland, Dublin, Ireland., Jerome N; The Royal Marsden NHS Foundation Trust & Institute for Cancer Research, London, United Kingdom., Caron H; Roche, Basel, Switzerland., Laidler J; University of Birmingham, Birmingham, United Kingdom., Fenwick N; University of Birmingham, Birmingham, United Kingdom., Holt G; University of Birmingham, Birmingham, United Kingdom., Moroz V; University of Birmingham, Birmingham, United Kingdom., Kearns P; University of Birmingham, Birmingham, United Kingdom., Gates S; University of Birmingham, Birmingham, United Kingdom., Pearson ADJ; The Royal Marsden NHS Foundation Trust & Institute for Cancer Research, London, United Kingdom., Wheatley K; University of Birmingham, Birmingham, United Kingdom.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 01; Vol. 42 (10), pp. 1135-1145. Date of Electronic Publication: 2024 Jan 08.

Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.

Autor: Carceller F; Paediatric and Adolescent Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, UK. Electronic address: Fernando.Carceller@icr.ac.uk., Bautista FJ; Department of Paediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Sud, Villejuif, France. Electronic address: franciscojose.bautista@salud.madrid.org., Jiménez I; Department of Paediatric, Adolescents and Young Adults Oncology, Institut Curie, Paris, France. Electronic address: irene.jimenez@curie.fr., Hladun-Álvaro R; Department of Paediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Sud, Villejuif, France. Electronic address: rhladun@vhebron.net., Giraud C; Department of Paediatric Clinical Trials, Institut Hématologique et d'Oncologie Pédiatrique, Lyon, France; Department of Paediatric Neuro-Oncology, Institut Hématologique et d'Oncologie Pédiatrique, Lyon, France. Electronic address: cecile.giraud@lyon.unicancer.fr., Bergamaschi L; Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: Luca.Bergamaschi@istitutotumori.mi.it., Dandapani M; Department of Paediatric Oncology, Birmingham Children's Hospital, Birmingham, UK. Electronic address: Madhumita.Dandapani@bch.nhs.uk., Aerts I; Department of Paediatric, Adolescents and Young Adults Oncology, Institut Curie, Paris, France. Electronic address: isabelle.aerts@curie.fr., Doz F; Department of Paediatric, Adolescents and Young Adults Oncology, Institut Curie, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, France. Electronic address: francois.doz@curie.fr., Frappaz D; Department of Paediatric Clinical Trials, Institut Hématologique et d'Oncologie Pédiatrique, Lyon, France; Department of Paediatric Neuro-Oncology, Institut Hématologique et d'Oncologie Pédiatrique, Lyon, France. Electronic address: didier.frappaz@ihope.fr., Casanova M; Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: Michela.Casanova@istitutotumori.mi.it., Morland B; Department of Paediatric Oncology, Birmingham Children's Hospital, Birmingham, UK. Electronic address: BRUCE.MORLAND@bch.nhs.uk., Hargrave DR; Paediatric Oncology Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address: Darren.Hargrave@gosh.nhs.uk., Marshall LV; Paediatric and Adolescent Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, UK. Electronic address: LynleyVanessa.Marshall@icr.ac.uk., Vassal G; Department of Clinical Research, Gustave Roussy, Université Paris-Sud, Villejuif, France. Electronic address: Gilles.Vassal@gustaveroussy.fr., Pearson AD; Paediatric and Adolescent Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, UK. Electronic address: andy1pearson@btinternet.com., Geoerger B; Department of Paediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Sud, Villejuif, France. Electronic address: Birgit.GEOERGER@gustaveroussy.fr., Moreno L; Clinical Trials Unit, Paediatric Oncology Department, Hospital Niño Jesús, Madrid, Spain. Electronic address: lmorenom@ext.cnio.es.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2016 Nov; Vol. 67, pp. 130-140. Date of Electronic Publication: 2016 Sep 21.